Towards Automated Manufacturing for Cell Therapies

Smith, David; Heathman, Thomas R.J.; Klarer, Alex; LeBlon, Courtney; Tada, Yutaka; Hampson, Brian

doi:10.1007/s11899-019-00522-y

Cited by 14 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The importance of software integration was reviewed recently [23]. Replacing manual batch manufacturing and quality control records with centralized electronic batch records allows for operational automation.…”

Section: Integrationmentioning

confidence: 99%

Advances in automated cell washing and concentration

Li¹,

Kusuma²,

Driscoll³

et al. 2021

Cytotherapy

View full text Add to dashboard Cite

The successful commercialization of cell therapies requires thorough planning and consideration of product quality, cost and scale of the manufacturing process. The implementation of automation can be central to a robust and reproducible manufacturing process at industrialized scales. There have been a number of washand-concentrate devices developed for cell manufacturing. These technologies have arisen from transfusion medicine, hematopoietic stem cell and biologics manufacturing where operating mechanisms are distinct from manual centrifugation. This review describes the historical origin and fundamental technologies underlying each currently available wash-and-concentrate device as well as their relative advantages and disadvantages in cell therapy applications. Understanding the specific attributes and limitations of these technologies is essential to optimizing cell therapy manufacturing.

show abstract

Section: Integrationmentioning

confidence: 99%

Advances in automated cell washing and concentration

Li¹,

Kusuma²,

Driscoll³

et al. 2021

Cytotherapy

View full text Add to dashboard Cite

show abstract

“…These results suggest that the reduction of C robo is restricted when the process cycle induces a low utilization rate of the robot arms. Reportedly, robotic operation and closed systems can effectively reduce the cost-of-goods [ 22 , 28 ]. Closed systems involve a liquid-handling operation system adopting sealed vessels, such as a culture tank, and do not require extended occupation of the CPZ in which the robot arms are installed.…”

Section: Resultsmentioning

confidence: 99%

“…For manufacturing using a master cell bank as raw material, the mechanization of cell-processing operations is an advantage for both the reproducibility and stability of product quality [ 20 ]. Indeed, it is assumed that robotic operations can increase reproducibility of product quality while reducing the cost of manufacturing [ 21 , 22 ]. Evaluating the cost-based effectiveness of cell manufacturing leads to reduced cost-of-goods in the life cycle of the product.…”

Section: Introductionmentioning

confidence: 99%

Approach of resource expenditure estimation toward mechanization in the manufacturing of cell-based products

Mizutani

Nakajima

Kino‐oka

2022

Regenerative Therapy

View full text Add to dashboard Cite

“…Other challenges that must be overcome to achieve cost-effective scalable manufacturing are apparent in other realms of cell therapy manufacturing as well. For instance, high facility operation costs could be reduced by the development of closed systems that enable use of lower-grade cleanrooms [35]; high labor costs could be reduced by the development of automated processes [36].…”

Section: Government and Philanthropic Investment Should Push The Deve...mentioning

confidence: 99%

Thinking ahead: developing biosynthetic blood to anticipate donor drought

Goldman¹,

Kilpatrick²,

Madrid³

et al. 2022

Cell Gene Therapy Insights

View full text Add to dashboard Cite

Advances in scientific research suggest the possibility of a viable biosynthetic blood technology that could radically transform the health outcomes of people around the world. Such a development would enhance a drastically insufficient global supply of red blood cells needed for transfusions, while also mitigating severe risks to donor supply precipitated by future pandemic or environmental catastrophes. However, insufficient funding is obstructing necessary further development. There is a pressing need for focused investment to advance scientific development, and an opportunity for government and philanthropic funds to help ensure that safe, efficacious biosynthetic blood becomes commercializable in a manner that enables global affordable access.

show abstract

Towards Automated Manufacturing for Cell Therapies

Cited by 14 publications

References 11 publications

Advances in automated cell washing and concentration

Advances in automated cell washing and concentration

Approach of resource expenditure estimation toward mechanization in the manufacturing of cell-based products

Thinking ahead: developing biosynthetic blood to anticipate donor drought

Contact Info

Product

Resources

About